Friday, September 30, 2011

Threshold cancer-fighting drug enters critical Phase III trial

Threshold Pharmaceuticals Inc. is set to launch a second Phase III trial of its cancer-fighting drug as it waits for critical data from another study in pancreatic cancer.
Results of the initial study, expected as soon as the end of the year or early 2012, are important for the Redwood City-based drug developer. It is the first randomized, controlled trial of Threshold’s signature drug, TH-302.

No comments:

Post a Comment